$INTI
Inhibitor Therapeutics, Inc. Stock $inti

$inti Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011973 Filed on March 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue		$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$539.5K	$588.4K	$2.024M
YoY Change	25.94%	38.88%	210.52%
% of Gross Profit
Research & Development	$235.4K	$684.9K	$1.381M
YoY Change	16.86%		22356.42%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$774.8K	$1.273M	$3.405M
YoY Change	23.04%	200.55%	417.53%
Operating Profit	-$774.8K		-$3.405M
YoY Change	23.04%		417.53%
Interest Expense	$90.11K	$106.0K	$378.8K
YoY Change		-3255.06%	1530.54%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$684.7K	-$1.167M	-$3.026M
YoY Change	26.89%	-109.4%	-124.88%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$684.7K	-$1.167M	-$3.026M
YoY Change	26.89%	-109.47%	-125.0%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00		-$0.02
Diluted Earnings Per Share	$0.00	-$0.01	-$0.02
COMMON SHARES
Basic Shares Outstanding	172.0M shares	172.0M shares	172.0M shares
Diluted Shares Outstanding	172.1M shares		172.0M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.682M	$8.840M	$8.840M
YoY Change	-28.76%	-26.03%	-26.03%
Cash & Equivalents	$7.700M	$8.840M	$8.840M
Short-Term Investments
Other Short-Term Assets	$112.4K	$109.2K	$109.2K
YoY Change	115.12%	357.07%	357.07%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$7.794M	$8.949M	$8.949M
YoY Change	-28.07%	-25.27%	-25.27%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$7.794M	$8.949M	$8.949M
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$7.794M	$8.949M	$8.949M
YoY Change	-28.07%	-25.27%	-25.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$111.9K	$33.73K	$33.73K
YoY Change	2135.19%	-76.76%	-76.76%
Accrued Expenses	$43.93K	$631.4K	$631.4K
YoY Change	-40.17%	414.94%	414.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$155.9K	$665.2K	$665.2K
YoY Change	98.68%	-2.01%	-2.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.000M	$3.000M	$3.000M
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Liabilities	$3.000M	$3.000M	$3.000M
YoY Change	0.0%	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$155.9K	$665.2K	$665.2K
Total Long-Term Liabilities	$3.000M	$3.000M	$3.000M
Total Liabilities	$3.156M	$3.665M	$3.665M
YoY Change	2.51%	-0.37%	-0.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$49.46M	-$48.78M
YoY Change	6.85%	6.61%
Common Stock	$17.23K	$17.20K
YoY Change	-99.97%	-99.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.638M	$5.284M	$5.284M
YoY Change
Total Liabilities & Shareholders Equity	$7.794M	$8.949M	$8.949M
YoY Change	-28.07%	-25.27%	-25.27%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$684.7K	-$1.167M	-$3.026M
YoY Change	26.89%	-109.47%	-125.0%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.158M	-$700.3K	-$2.700M
YoY Change	52.93%	-105.89%	-123.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-1.000K	-411.0K
YoY Change			-328.33%
NET CHANGE
Cash From Operating Activities	-$1.158M	-700.3K	-2.700M
Cash From Investing Activities
Cash From Financing Activities		-1.000K	-411.0K
Net Change In Cash	-$1.158M	-701.3K	-3.111M
YoY Change	-0.87%	-105.89%	-126.1%
FREE CASH FLOW
Cash From Operating Activities	-$1.158M	-$700.3K	-$2.700M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Interest Expense InterestExpense		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Revenues Revenues		usd
CY2022	us-gaap	Revenues Revenues		usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
CY2023	INTI	Gain On Forgiveness Of Cancellation On Legal Fees GainOnForgivenessOfCancellationOnLegalFees		usd
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2022	INTI	Stock Cancelled During Period Value StockCancelledDuringPeriodValue		usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2023	INTI	Gain Related To Litigation Settlement GainRelatedToLitigationSettlement		usd
CY2023	INTI	Gain On Forgiveness Of Legal Fees GainOnForgivenessOfLegalFees		usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2023	INTI	Cancellation Of Equity CancellationOfEquity		usd
CY2023	INTI	Accrued But Unpaid Dividends AccruedButUnpaidDividends		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	INTI	Deferred Tax Assets Operating Loss Carryforwards Capitalized Research Expense DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedResearchExpense		usd
CY2022Q4	INTI	Deferred Tax Assets Tax Credit Carryforwards Income DeferredTaxAssetsTaxCreditCarryforwardsIncome		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	3200000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	172023545	shares
CY2023	dei	Auditor Firm AuditorFirmId	677
CY2023	dei	Auditor Name AuditorName	Cherry Bekaert LLP
CY2023	dei	Auditor Location AuditorLocation	Tampa, Florida
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8839912	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11951224	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	109243	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23900	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	8949155	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	11975124	usd
CY2023Q4	us-gaap	Assets Assets	8949155	usd
CY2022Q4	us-gaap	Assets Assets	11975124	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	33731	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	145161	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	411000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	631433	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	122621	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	665164	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	678782	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3000000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3000000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3665164	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3678782	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	172023545	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	172023545	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	171793134	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	171793134	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	17202	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	17179	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	54046845	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	54033084	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-48780056	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45753921	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5283991	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	8296342	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8949155	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11975124	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1381066	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6150	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2023913	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	651776	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	657926	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	12619492	usd
CY2022	INTI	Gain On Forgiveness Of Cancellation On Legal Fees GainOnForgivenessOfCancellationOnLegalFees	223007	usd
CY2022	us-gaap	Interest Expense InterestExpense	23234	usd
CY2023	us-gaap	Interest And Other Income InterestAndOtherIncome	378844	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3026135	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	12161339	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	55109	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3026135	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	12106230	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	189042	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3026135	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	11917188	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	171950108	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	171950108	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	366183697	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	366183697	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3620846	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	189042	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	12106230	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	8296342	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	13784	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3026135	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3026135	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5283991	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5283991	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3026135	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	12106230	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	13784	usd
CY2022	INTI	Gain Related To Litigation Settlement GainRelatedToLitigationSettlement	330830	usd
CY2022	INTI	Gain On Forgiveness Of Legal Fees GainOnForgivenessOfLegalFees	176889	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	85343	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4258	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	397382	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	137829	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2700312	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	11740598	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	180000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	411000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-411000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	180000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3111312	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11951224	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8839912	usd
CY2022	INTI	Cancellation Of Equity CancellationOfEquity	3981373	usd
CY2022	INTI	Accrued But Unpaid Dividends AccruedButUnpaidDividends	189042	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	53088	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8800000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zhZiJ7NOSxJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	230411	shares
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	22850	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	32259	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	55109	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	55109	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-635488	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	2514182	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-131486	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	520196	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	45096	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-70951	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	721878	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2908318	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	55109	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	742574	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	742574	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3516913	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3870413	usd
CY2023Q4	INTI	Deferred Tax Assets Operating Loss Carryforwards Capitalized Research Expense DeferredTaxAssetsOperatingLossCarryforwardsCapitalizedResearchExpense	315028	usd
CY2023Q4	INTI	Deferred Tax Assets Tax Credit Carryforwards Income DeferredTaxAssetsTaxCreditCarryforwardsIncome	760350	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	78336	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	78336	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	34231	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	34231	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6061	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6061	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5453493	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4731615	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5453493	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4731615	usd
CY2023	us-gaap	Valuation Allowance Methodologies And Assumptions ValuationAllowanceMethodologiesAndAssumptions	In accordance with GAAP, it is required that a deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than 50%) that some portion or all of the deferred tax assets will not be realized.
CY2023Q4	INTI	Percentage Of Deferred Tax Assets Valuation Allowance PercentageOfDeferredTaxAssetsValuationAllowance	1	pure
CY2022Q4	INTI	Percentage Of Deferred Tax Assets Valuation Allowance PercentageOfDeferredTaxAssetsValuationAllowance	1	pure
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	17000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13349461	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.10
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1072144	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	10773815	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2575646	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.09
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	111774	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2575646	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.09
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	93633	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2575646	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	93633	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	55000	usd

Files In Submission

Name	View Source	Status
0001493152-24-011973-index-headers.html	Edgar Link	pending
0001493152-24-011973-index.html	Edgar Link	pending
0001493152-24-011973.txt	Edgar Link	pending
0001493152-24-011973-xbrl.zip	Edgar Link	pending
ex10-6.htm	Edgar Link	pending
ex10-6_001.jpg	Edgar Link	pending
ex10-6_004.jpg	Edgar Link	pending
ex10-6_005.jpg	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
inti-20231231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
inti-20231231_cal.xml	Edgar Link	unprocessable
inti-20231231_def.xml	Edgar Link	unprocessable
inti-20231231_lab.xml	Edgar Link	unprocessable
inti-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INTI
Inhibitor Therapeutics, Inc. Stock $inti

2024 Q1 Form 10-K Financial Statement

#000149315224011973 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INTI Inhibitor Therapeutics, Inc. Stock $inti

2024 Q1 Form 10-K Financial Statement

#000149315224011973 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INTI
Inhibitor Therapeutics, Inc. Stock $inti